Report Company Directory

BIOSYNTECH INC

Biotage AB

• Biotage - Termination of coverage by Danske Bank Equity Research
• Biotage - No Rating: Termination of coverage by Nordea
• Biotage AB: 1 director by SmartInsider
• Biotage - Saved by the bell by Danske Bank Equity Research
• Biotage - No Rating: Suspension of recommendation and target price by Nordea
• Sartorius reports a decline in LPS sales in Q1 as customers continue to postpone capital equipment investments by Nordea
• Swedish small cap weekly: Week 15 – New addition to the portfolio by Nordea
• Biotage - Buy/SEK 135 (158): Growth recovery in Small Molecules by Nordea
• Swedish small cap weekly: Week 14 – Onwards and upwards by Nordea
• Swedish small cap weekly: Week 13 – Long-term cases intact by Nordea

BIOTAGE AB

• Swedish small cap weekly: Week 15 – New addition to the portfolio by Nordea
• Biotage - Buy/SEK 135 (158): Growth recovery in Small Molecules by Nordea
• Swedish small cap weekly: Week 13 – Long-term cases intact by Nordea
• Swedish small cap weekly: Week 12 – Gone global: China and Germany by Nordea
• Biotage - Buy : Wuxi Chemistry beats consensus; growth acceleration in 2025 by Nordea
• Swedish small cap weekly: Week 10 – New companies on board by Nordea
• Swedish small cap weekly: Week 9 – A triple jackpot by Nordea
• Thermo Fisher guide for solid market growth in 2025 by Nordea
• Danaher Q4 and 2025 guidance by Nordea
• Astrea supplies resins to Thermo Fisher's CaptureSelect products by Nordea

BIOTALYS NV

• Morning Notes : JEN BB, MONT BB, BTLS BB, AUTL US by KBC Securities
• Biotalys Received regulatory approval for Evoca by KBC Securities
• Biotalys EPA issues proposed registration decision for Evoca by KBC Securities
• Morning Notes : FUR NA, GLPG NA, MTLS US, QFG BB, XFAB FP, BTLS BB, SYENS BB, ECMPA NA by KBC Securities
• Morning Notes : NEXTA BB, SOF BB, UCB BB, BTLS BB, ONWD BB, EXO NA by KBC Securities
• Biotalys 1H25 underscores its prudent and cost-efficient operating strategy by KBC Securities
• Morning Notes : ACKB BB, HAL NA, NEXTA BB, RECT BB, RET BB, UCB BB, BTLS BB, ECMPA NA by KBC Securities
• Biotalys EPA's review on Evoca in 4Q rather than by end September by KBC Securities
• (Sponsored) Biotalys NV - Fungal foes, natural fixes by Degroof Petercam
• Morning Notes : ARGX BB, BFIT NA, PNL NA, QFG BB, UMI BB, BTLS BB, ONWD BB, JDEP NA by KBC Securities

Biotec Pharmacon ASA

• ArcticZymes Technologies – Buy/NOK 33: Promising in vivo CAR-T data from Kelonia Therapeutics by Nordea
• ArcticZymes Technologies – Buy/NOK 33: Merck KGaA reports continued strong sales growth in Process Solutions by Nordea
• ArcticZymes Technologies – Buy/NOK 33 (34): Mixed Q3 numbers but a solid growth outlook by Nordea
• ArcticZymes Technologies – Buy/NOK 34: First take Q3 - Sales slightly below expectations, offset by stronger margins by Nordea
• ArcticZymes Technologies – Buy/NOK 34: SAN distribution agreement with Brenntag Specialties Pharma by Nordea
• ArcticZymes Technologies – Buy/NOK 34 (28):Big things are cooking by Nordea
• ArcticZymes Technologies – Buy/NOK 28: Acceleration in US funding to in vivo cell therapies by Nordea
• ArcticZymes Technologies – Buy/NOK 28: Umoja Biopharma received the first in vivo CAR-T FDA Fast Track Designation by Nordea
• US Life Science Tools stocks surge following Pfizer deal by Nordea
• ArcticZymes Technologies – Buy/NOK 28: OXB issues shares to further invest in growth and process development; forecasts ~40% y/y sales growth in 2026 by Nordea